BR112019022901A2 - precursor de linhagem mesenquimal ou células t com imunossupressão intensificada - Google Patents

precursor de linhagem mesenquimal ou células t com imunossupressão intensificada Download PDF

Info

Publication number
BR112019022901A2
BR112019022901A2 BR112019022901-9A BR112019022901A BR112019022901A2 BR 112019022901 A2 BR112019022901 A2 BR 112019022901A2 BR 112019022901 A BR112019022901 A BR 112019022901A BR 112019022901 A2 BR112019022901 A2 BR 112019022901A2
Authority
BR
Brazil
Prior art keywords
mesenchymal lineage
cells
precursor
gvhd
precursors
Prior art date
Application number
BR112019022901-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Itescu Silviu
Simmons Paul
Original Assignee
Mesoblast International Sàrl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901633A external-priority patent/AU2017901633A0/en
Application filed by Mesoblast International Sàrl filed Critical Mesoblast International Sàrl
Publication of BR112019022901A2 publication Critical patent/BR112019022901A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112019022901-9A 2017-05-04 2018-05-04 precursor de linhagem mesenquimal ou células t com imunossupressão intensificada BR112019022901A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2017901633 2017-05-04
AU2017901633A AU2017901633A0 (en) 2017-05-04 Potency assay for immunosuppression
AU2017901636A AU2017901636A0 (en) 2017-05-04 Method for treating Graft versus Host Disease (GVHD)
AU2017901636 2017-05-04
AU2018900551A AU2018900551A0 (en) 2018-02-21 Potency assay for immunosuppression II
AU2018900551 2018-02-21
PCT/EP2018/061503 WO2018202853A1 (en) 2017-05-04 2018-05-04 Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Publications (1)

Publication Number Publication Date
BR112019022901A2 true BR112019022901A2 (pt) 2020-05-19

Family

ID=62222586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019022901-9A BR112019022901A2 (pt) 2017-05-04 2018-05-04 precursor de linhagem mesenquimal ou células t com imunossupressão intensificada

Country Status (10)

Country Link
US (1) US20200325450A1 (https=)
EP (2) EP4137562A1 (https=)
JP (3) JP7398959B2 (https=)
KR (2) KR102660506B1 (https=)
CN (1) CN110753751A (https=)
AU (2) AU2018262788B2 (https=)
BR (1) BR112019022901A2 (https=)
CA (1) CA3062112A1 (https=)
SG (1) SG11201909856XA (https=)
WO (1) WO2018202853A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
SG11201909856XA (en) * 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
KR20220143092A (ko) * 2020-02-19 2022-10-24 메조블라스트 인터내셔널 에스에이알엘 만성 이식편 대 숙주 질환의 치료 방법
JP7793284B2 (ja) * 2020-03-02 2026-01-05 株式会社ガイアバイオメディシン 高活性ｎｋ細胞の処理方法
JP2023530098A (ja) * 2020-06-11 2023-07-13 メゾブラスト・インターナショナル・エスアーエールエル 間葉系前駆細胞又は幹細胞の３ｄ培養
AU2021323475A1 (en) * 2020-08-10 2023-04-13 Mesoblast International Sarl A composition comprising mesenchymal precursor or stem cells and their use
CN112444479B (zh) * 2021-02-01 2021-05-07 宁波大学 基于并行处理技术的单细胞质谱分析系统及方法
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
US20250032552A1 (en) * 2021-12-23 2025-01-30 Mesoblast International Sárl Method of treating severe graft versus host disease
CA3260880A1 (en) * 2022-07-05 2024-01-11 Mesoblast International Sarl CRYOPROVERTED INTERMEDIATE AND BIOLOGICAL ACTIVITY TEST FOR IT
KR20250049337A (ko) 2022-08-09 2025-04-11 엑손모빌 케미칼 패턴츠 인코포레이티드 디페닐실란 가교 c1 대칭 촉매의 제조 방법 및 이로부터 제조된 중합체
WO2024168161A1 (en) * 2023-02-08 2024-08-15 Mesoblast International Sarl Potency assay and manufacturing method
WO2025196663A1 (en) * 2024-03-19 2025-09-25 Mesoblast International Sarl Potency assay and manufacturing method ii
CN118147232B (zh) * 2024-05-09 2024-07-19 中国人民解放军联勤保障部队第九二〇医院 一种过表达tps1间充质干细胞的构建方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
WO1994026877A1 (en) 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6566051B1 (en) 1999-01-15 2003-05-20 Medtox Scientific, Inc. Lateral flow test strip
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
CN101248171B (zh) 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
KR101891260B1 (ko) * 2010-07-02 2018-08-24 메소블라스트, 아이엔씨. T-세포 매개된 면역 질환의 치료
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
SG11201607925SA (en) * 2014-04-07 2016-10-28 Mesoblast Internat Sarl Improved stem cell composition
EP3236977B1 (en) * 2014-12-23 2023-06-21 Mesoblast International Sàrl Method for treating heart failure
SG11201909856XA (en) 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Also Published As

Publication number Publication date
JP2020518260A (ja) 2020-06-25
WO2018202853A1 (en) 2018-11-08
EP4137562A1 (en) 2023-02-22
KR102884611B1 (ko) 2025-11-12
SG11201909856XA (en) 2019-11-28
KR102660506B1 (ko) 2024-04-25
EP3619294A1 (en) 2020-03-11
US20200325450A1 (en) 2020-10-15
AU2018262788B2 (en) 2024-08-15
KR20200003044A (ko) 2020-01-08
JP2026034487A (ja) 2026-02-27
JP7787130B2 (ja) 2025-12-16
JP2023174760A (ja) 2023-12-08
JP7398959B2 (ja) 2023-12-15
CA3062112A1 (en) 2018-11-08
AU2024227344A1 (en) 2024-10-31
CN110753751A (zh) 2020-02-04
KR20240056790A (ko) 2024-04-30
AU2018262788A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
BR112019022901A2 (pt) precursor de linhagem mesenquimal ou células t com imunossupressão intensificada
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
WO2019094642A8 (en) T cell manufacturing compositions and methods
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2017000646A (es) Celulas geneticamente modificadas para terapia celular adoptiva.
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
SG10201803533YA (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX2020005640A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
JO3543B1 (ar) تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
MX383650B (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
MX385336B (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
BR112012016543A2 (pt) Tratamento com vb-201
MX2019012465A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25.
PH12016502307A1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX383292B (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX386938B (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
HK1263322A1 (zh) 使用长双歧杆菌调节情绪反应性并治疗或预防亚临床心境紊乱的方法和组合物
AU2018285562A1 (en) Dosage regimes for the administration of an anti-CD19 ADC
BR112022007721A2 (pt) Método para o tratamento da demência

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]